Recombinant MSCs (mesenchymal stem cells) as well as preparation method and application thereof in preparation of drug for treating ALF (acute liver failure)
A technology of stem cells and recombinant plasmids, applied in the field of biomedicine, can solve the problems of liver cell necrosis, restrict curative effect, liver damage to liver function, etc., and achieve the effects of reducing inflammatory response, improving therapeutic efficacy, and promoting liver regeneration.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Publication Date
- 2020-06-05
- Estimated Expiration
- Not applicable · inactive patent
Smart Images

Figure 1 
Figure 2 
Figure 3
Abstract
Description
technical field
[0001] The invention belongs to the field of biomedicine and relates to the application of a medicine for treating acute liver failure, in particular to a recombinant mesenchymal stem cell and its preparation method and its application in the preparation of medicine for treating acute liver failure. Background technique
[0002] Acute liver failure (ALF) is a severe clinical disease characterized by rapid and massive necrosis of liver cells and a sharp decline in liver function. At present, liver transplantation is the most effective method for the treatment of ALF, but its application is limited due to the shortage of donor liver sources. Stem cell transplantation has been considered an effective way to treat a variety of liver diseases, and mesenchymal stem cells (MSCs) are just one of them, which have been proven to alleviate a variety of acute or chronic liver diseases. However, the results of clinical trials show that the therapeutic effect is not satis...
Examples
Embodiment Construction
[0026] The present invention will be further described below in conjunction with specific examples.
[0027] The invention provides a recombinant mesenchymal stem cell obtained by infecting the mesenchymal stem cell with a recombinant lentivirus. Wherein, the recombinant lentivirus is obtained by transfecting cells with a recombinant plasmid overexpressing PTGS2 and a lentiviral packaging vector. Overexpression of PTGS2 promotes PGE 2 secretion. The recombinant plasmid for overexpression of PTGS2 was obtained by amplifying the pre-primer sequence and back-primer sequence of PTGS2, and the empty plasmid vector Ubi-MCS-3FLAG-CBh-gcGFP-IRES-pu romycin.
[0028] A method for preparing recombinant mesenchymal stem cells, comprising the following steps:
[0029] Step 1. Isolation of mesenchymal stem cells.
[0030] 1. Isolation of mouse mesenchymal stem cells.
[0031] 1) Under sterile conditions, remove the femur and tibia of a 4-week-old mouse to expose the bone marrow cavity...